These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 29976634)

  • 61. Biomarkers of intrahepatic cholangiocarcinoma: diagnosis and response to therapy.
    Brown ZJ; Hewitt DB; Pawlik TM
    Front Biosci (Landmark Ed); 2022 Mar; 27(3):85. PubMed ID: 35345317
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Subclassification and Detection of New Markers for the Discrimination of Primary Liver Tumors by Gene Expression Analysis Using Oligonucleotide Arrays.
    Hass HG; Vogel U; Scheurlen M; Jobst J
    Gut Liver; 2018 May; 12(3):306-315. PubMed ID: 29271183
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Comparison of hepatocellular carcinoma (HCC), cholangiocarcinoma (CC), and combined HCC-CC (CHC) with each other based on microarray dataset.
    Wang L
    Tumour Biol; 2013 Jun; 34(3):1679-84. PubMed ID: 23532688
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The value of gadobenate dimeglumine-enhanced hepatobiliary-phase MR imaging for the differentiation of scirrhous hepatocellular carcinoma and cholangiocarcinoma with or without hepatocellular carcinoma.
    Jeon TY; Kim SH; Lee WJ; Lim HK
    Abdom Imaging; 2010 Jun; 35(3):337-45. PubMed ID: 19350315
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Clinical Characterization of HCC/CCA Mixed Cancers in a Population-based Cohort.
    Teufel A; Rodriguez I; Winzler C; Kokh D; Ebert MP; Surovtsova I; Morakis P
    J Gastrointestin Liver Dis; 2023 Jun; 32(2):190-196. PubMed ID: 37345609
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Whole-exome mutational and transcriptional landscapes of combined hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma reveal molecular diversity.
    Liu ZH; Lian BF; Dong QZ; Sun H; Wei JW; Sheng YY; Li W; Li YX; Xie L; Liu L; Qin LX
    Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2360-2368. PubMed ID: 29408647
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Positive expression of Midkine predicts early recurrence and poor prognosis of initially resectable combined hepatocellular cholangiocarcinoma.
    Ma MC; Chen YJ; Chiu TJ; Lan J; Liu CT; Chen YC; Tien HH; Chen YY
    BMC Cancer; 2018 Feb; 18(1):227. PubMed ID: 29486735
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Combined hepatocellular-cholangiocarcinoma with angiosarcomatoid change: A case report with immunohistochemical study.
    Hakozaki M; Ito S; Fujii T; Kiya Y; Udagawa H; Fukayama M; Fukusato T
    Pathol Int; 2019 Feb; 69(2):110-116. PubMed ID: 30672653
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Mixed hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma in patients undergoing transplantation for hepatocellular carcinoma.
    Sapisochin G; Fidelman N; Roberts JP; Yao FY
    Liver Transpl; 2011 Aug; 17(8):934-42. PubMed ID: 21438129
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Effect of liver transplantation in combined hepatocellular and cholangiocellular carcinoma: a case series.
    Wu D; Shen ZY; Zhang YM; Wang J; Zheng H; Deng YL; Pan C
    BMC Cancer; 2015 Apr; 15():232. PubMed ID: 25886479
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [The significance of immunohistochemistry in the investigation of liver neoplasms: differential diagnosis, prognostic markers].
    Pozharisskiĭ KM; Granov DA; Ten VP; Kubaĭbergenova AG; Leenman EE; Rasskazov AI
    Vopr Onkol; 2008; 54(4):417-33. PubMed ID: 18942395
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Combined hepatocellular-cholangiocarcinoma derives from liver progenitor cells and depends on senescence and IL-6 trans-signaling.
    Rosenberg N; Van Haele M; Lanton T; Brashi N; Bromberg Z; Adler H; Giladi H; Peled A; Goldenberg DS; Axelrod JH; Simerzin A; Chai C; Paldor M; Markezana A; Yaish D; Shemulian Z; Gross D; Barnoy S; Gefen M; Amran O; Claerhout S; Fernández-Vaquero M; García-Beccaria M; Heide D; Shoshkes-Carmel M; Schmidt Arras D; Elgavish S; Nevo Y; Benyamini H; Tirnitz-Parker JEE; Sanchez A; Herrera B; Safadi R; Kaestner KH; Rose-John S; Roskams T; Heikenwalder M; Galun E
    J Hepatol; 2022 Dec; 77(6):1631-1641. PubMed ID: 35988690
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Clinicopathological factors impact the survival outcome following the resection of combined hepatocellular carcinoma and cholangiocarcinoma.
    Yap AQ; Chen CL; Yong CC; Kuo FY; Wang SH; Lin CC; Liu YW; Lin TL; Li WF; Millan CA; Wang CC
    Surg Oncol; 2013 Mar; 22(1):55-60. PubMed ID: 23102615
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Hepatocellular carcinoma and cholangiocarcinoma--different prognosis, pathogenesis and therapy].
    Tischoff I; Tannapfel A
    Zentralbl Chir; 2007 Aug; 132(4):300-5. PubMed ID: 17724632
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Spatial and temporal clonal evolution of intrahepatic cholangiocarcinoma.
    Dong LQ; Shi Y; Ma LJ; Yang LX; Wang XY; Zhang S; Wang ZC; Duan M; Zhang Z; Liu LZ; Zheng BH; Ding ZB; Ke AW; Gao DM; Yuan K; Zhou J; Fan J; Xi R; Gao Q
    J Hepatol; 2018 Jul; 69(1):89-98. PubMed ID: 29551704
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Global DNA methylation and hydroxymethylation differ in hepatocellular carcinoma and cholangiocarcinoma and relate to survival rate.
    Udali S; Guarini P; Moruzzi S; Ruzzenente A; Tammen SA; Guglielmi A; Conci S; Pattini P; Olivieri O; Corrocher R; Choi SW; Friso S
    Hepatology; 2015 Aug; 62(2):496-504. PubMed ID: 25833413
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Long-term prognosis of combined hepatocellular and cholangiocarcinoma after curative resection comparison with hepatocellular carcinoma and cholangiocarcinoma.
    Lee JH; Chung GE; Yu SJ; Hwang SY; Kim JS; Kim HY; Yoon JH; Lee HS; Yi NJ; Suh KS; Lee KU; Jang JJ; Kim YJ
    J Clin Gastroenterol; 2011 Jan; 45(1):69-75. PubMed ID: 20142755
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Potential diagnostic performance of contrast-enhanced ultrasound and tumor markers in differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and cholangiocarcinoma.
    Huang XW; Huang Y; Chen LD; Wang Z; Yang Z; Liu JY; Xie XY; Lu MD; Shen SL; Wang W
    J Med Ultrason (2001); 2018 Apr; 45(2):231-241. PubMed ID: 29052791
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Clinicopathologic features and diagnosis of mixed type hepatocellular carcinoma].
    Lu J; Lin Z; Yuan S
    Zhonghua Zhong Liu Za Zhi; 1995 May; 17(3):208-11. PubMed ID: 7656828
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencing.
    Putra J; de Abreu FB; Peterson JD; Pipas JM; Mody K; Amos CI; Tsongalis GJ; Suriawinata AA
    Exp Mol Pathol; 2015 Oct; 99(2):240-4. PubMed ID: 26189129
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.